The infectologist Fernando Polack affirmed that thanks to the advances that occurred from the development of the coronavirus vaccine, pharmaceutical companies are working on a triple vaccine to treat in a combined way covid-19, influenza and respiratory syncytial virus. Argentine scientists also participate in this research.
“The possibility of new vaccines against the three viruses was opened. The goal is to eventually migrate to a vaccine, as if it were the boys’ MMR: measles-mumps-rubella, but an adult MMR, ”Polack said.
The infectologist stressed that “Phase two studies are very successful”, and said that the third phase will take place in Argentina, as happened with the Pfizer vaccine.
Polack stressed that during the pandemic The technological “leap” was the creation of messenger RNA vaccinesSuch as the vaccines from Moderna and Pfizer laboratories, which by making the body believe that it is infected, the immune system seeks to defend itself and generates antibodies.
In dialogue with Radio Miter, the specialist was optimistic about the possible creation of a triple vaccine to also treat influenza and respiratory syncytial virus. “The flu vaccine has a maximum efficacy of around 60 and 70 percent, the year we get it right with the vaccine,” he said and warned that in winter there was a “very high” number of people who had an episode of flu prior to having a heart attack.
“The flu vaccine has deltas, ranges and alphas that are very difficult to get right,” he said. Now a total change is coming because, With the new vaccines the aim is to achieve things very similar to those achieved with the coronavirus”.
Polack also affirmed that the respiratory syncytial virus exceeds the flu as a cause of hospitalization and that its danger lies in the fact that “there is no protection.” “It is in large people and it is very common in babies; in fact, it is the bronchiolitis virus ”, he concluded.
– .
